Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.31 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.31 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 2/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11933255 | 0.97 | MAPT (0.37) | MAPTSMN1; SMN2ALOX5APFEN1CAMKK1 | |
| SCHEMBL11933347 | 0.97 | MAPT (0.37) | MAPTSMN1; SMN2ALOX5APFEN1CAMKK1 | |
| SCHEMBL10091366 | 0.96 | MAPT (0.37) | MAPTSMN1; SMN2CAMKK1CAMKK2SGPL1 | |
| SCHEMBL14922594 | 0.95 | MAPT (0.36) | MAPTSMN1; SMN2ALOX5APFEN1CAMKK1 | |
| SCHEMBL12197181 | 0.93 | MAPT (0.39) | MAPTSMN1; SMN2CAMKK1CAMKK2SGPL1 | |
| SCHEMBL12197268 | 0.93 | SCN9A (0.35) | MAPTSMN1; SMN2ALOX5APFEN1HPGD | |
| SCHEMBL15381579 | 0.92 | MAPT (0.37) | MAPTSMN1; SMN2ALOX5APFEN1CAMKK1 | |
| SCHEMBL15381720 | 0.92 | MAPT (0.37) | MAPTSMN1; SMN2ALOX5APFEN1CAMKK1 | |
| SCHEMBL12223556 | 0.90 | MAPT (0.33) | MAPTSMN1; SMN2CAMKK1CAMKK2FPR2 | |
| SCHEMBL14922672 | 0.90 | FPR2 (0.33) | MAPTSMN1; SMN2ALOX5APFEN1CAMKK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435422-B2 | Five-ring compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NCAPD3, CCND3, ZKSCAN2 | MAPT 1000/4885SMN1; SMN2 3764/4885ALOX5AP 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.